BURSOR & FISHER, P.A.		
Neal J. Deckant (State Bar No. 322946)		
Luke Sironski-White (State Bar No. 34844	-1)	
Facsimile: (925) 407-2700		
E-mail: ndeckant@bursor.com		
lsironski@bursor.com		
Attorneys for Plaintiffs		
UNITED STATES DISTRICT COURT		
SOUTHERN DISTRICT OF CALIFORNIA		
C.B. and R.V.H., individually and on behalf of all others similarly situated,	Case No.	
Plaintiffs	CLASS ACTION COMPLAINT	
	CLASS ACTION COMI LAINT	
ASHLYNN MARKETING GROUP, INC.,	JURY TRIAL DEMANDED	
Defendant.		
	Neal J. Deckant (State Bar No. 322946) Luke Sironski-White (State Bar No. 34844 1990 North California Blvd., Suite 940 Walnut Creek, CA 94596 Telephone: (925) 300-4455 Facsimile: (925) 407-2700 E-mail: ndeckant@bursor.com lsironski@bursor.com Attorneys for Plaintiffs UNITED STATES I SOUTHERN DISTRIC	

CLASS ACTION COMPLAINT – JURY TRIAL DEMANDED

4

5

6 7

8 9

10 11

12 13

14

15

16

17

18

19 20

21

22 23

24 25

26 27

28

Plaintiffs C.B. and R.V.H. ("Plaintiffs") bring this action on behalf of themselves and all others similarly situated against Defendant Ashlynn Marketing Group, Inc., d/b/a Krave Botanicals ("Defendant" or "Krave").

NATURE OF THE ACTION

- This is a civil class action lawsuit against Defendant Ashlynn Marketing 1. Group, Inc. for false, misleading, deceptive, and negligent sales practices regarding its kratom powder, capsule, and liquid extract products (the "Products"). Kratom is a dried leaf that is sold as a loose powder, packaged into gel caps, or made into an extract. However, what reasonable consumers do not know, and what Defendant fails to disclose, is that the "active ingredients" in kratom are similar to opioids. That is, kratom works on the exact same opioid receptors in the human brain as morphine and its analogs, has similar effects as such, and critically, has similar risks of physical addiction and dependency, with similar withdrawal symptoms. When reasonable consumers think of opiates and opioids, they think of heroin, fentanyl, hydrocodone, oxycodone, and morphine; they do not expect that the "all natural" product bought at their local corner store operates like an opioid, with similar addiction and dependency risks. Kratom is perniciously addictive – on a whole different level than caffeine or nicotine – and it has sunk its hooks into tens of thousands of unsuspecting consumers and caused them serious physical, psychological, and financial harm. Here, Defendant intentionally and negligently failed to disclose these material facts anywhere on its labeling, packaging, or marketing materials, and it has violated warranty law and state consumer protection laws in the process.
- Defendant relies on its Products' innocuous packaging and the public's 2 limited knowledge about kratom and its pharmacology to get users addicted, while reaping profits along the way. Reasonable consumers do not expect the bottles and pouches of kratom powder, which they can purchase at gas stations and corner stores, to be like an opioid with the same addictive potential of morphine and its

analogs. Defendant relies on this ignorance and does nothing to correct it. Such activity is outrageous and is in contravention of California law and public policy.

- 3. Plaintiffs seek relief in this action individually and as a class action on behalf of similarly situated purchasers of Defendant's Products, for: (i) violation of California's Unfair Competition Law ("UCL"), Cal. Bus. & Prof. Code §§ 17200, et seq.; (ii) violation of California's Consumers Legal Remedies Act ("CLRA"), Cal. Civil Code §§ 1750, et seq.; (iii) violation of California's False Advertising Law ("FAL"), Cal. Bus. & Prof. Code §§ 17500, et seq.; (iv) breach of implied warranty; (v) unjust enrichment; (vi) fraud by omission; and (vii) negligent misrepresentation.
- 4. Because this action concerns issues of addiction and medical status, Plaintiffs are filing under their initials for the sake of their personal privacy. Plaintiffs are reasonable consumers who fell victim to Defendant's omissions and misrepresentations about the addictive nature of kratom, which operates like an opioid, and became addicted as a result. Since addiction issues still wrongly carry somewhat of a stigma, Plaintiffs are filing this matter anonymously but will reveal their names as necessary to the Court under seal.

PARTIES

- 5. Plaintiff R.V.H. is a citizen of Arizona who resides in Yuma, Arizona.
- 6. Plaintiff C.B. is a citizen of California who resides in Encinitas, California.
- 7. Defendant Ashlynn Marketing Group, Inc., is a California corporation with its principal place of business in Santee, California.
- 8. Plaintiffs reserve the right to amend this Complaint to add different or additional defendants, including without limitation any officer, director, employee, supplier, or distributor of Defendant who has knowingly and willfully aided, abetted, and/or conspired in the false and deceptive conduct alleged herein.

JURISDICTION AND VENUE

- 9. This Court has subject matter jurisdiction pursuant to 28 U.S.C. § 1332(d)(2)(A) because this case is a class action where the aggregate claims of all members of the proposed class are in excess of \$5,000,000.00, exclusive of interest and costs, and at least one member of the proposed class is citizen of state different from Defendant.
- 10. This Court has general jurisdiction over Defendant because Defendant is a California corporation and maintains its principal place of business within this District.
- 11. Pursuant to 28 U.S.C. § 1391, this Court is the proper venue for this action because Defendant resides in this District.

FACTUAL ALLEGATIONS

Background and Pharmacology of Kratom

- 12. Kratom is a drug¹ which is derived from the kratom plant, *mitragyna speciosa*, indigenous to Southeast Asia, where it has been used in herbal medicine since at least the early 19th Century. Use of the plant has been particularly well-documented in Thailand, Indonesia, and Malaysia, and it remains popular in each of those countries to this day. Kratom is the most widely used drug in Thailand, for example.
- 13. The first reported use of Kratom in the scientific literature dates back to 1836 when it was noted that the leaves of the tree were used by Malays as a substitute for opium.
- 14. The plant's leaves are harvested, dried, and crushed into a fine powder which is then packaged, either straight into a pouch or in capsules, and sold by manufacturers like Krave. The drug can also be extracted into a liquid formulation, colloquially called a kratom "shot."

¹ Kratom is unregulated by the FDA, so the usage of the word "drug" here is meant in the colloquial sense, rather than as a defined term under the Food, Drug, and Cosmetic Act.

- 15. In the West, Kratom is sold through the Internet and at herbal stores, gas stations, corner stores, smoke shops, and "head" shops where it is primarily marketed as an herbal medicine or supplement to treat a variety of ailments (*e.g.*, pain, mental health, opioid withdrawal symptoms), as well as a "legal" or "natural" high by some manufacturers.
- 16. The chemicals in the plant which produce psychoactive effects when ingested are called "alkaloids."
- 17. The primary alkaloids in kratom plant leaves responsible for the kratom "high" are Mitragynine² ("MG") and 7-hydroxymitragynine ("7-MG").
- 18. MG and 7-MG exhibit a wide variety of pharmacological effects, resulting in a highly dose-dependent response. For example, a low dose (0.5 grams to 3 grams) of kratom is typically described as stimulating or energizing, whereas a high dose (3+ grams) is described as euphoric, sedating, and analgesic. On the whole, however, kratom's high is not overwhelming like it would be for a "hard" drug like cocaine or heroin it is somewhat more subtle, but its effects are nonetheless substantially similar to opiate-based painkillers such as hydrocodone and oxycodone in sufficient dosages.
- 19. Kratom's variable but not debilitating effects have always been part of its appeal. For instance, the use of kratom in Southeast Asia has been documented back for at least 150 years, and the earliest accounts described both a stimulant effect for use in hard day-labor when fresh leaves are chewed, and an analgesic and relaxing effect if brewed into a tea at the end of the day.
- 20. MG and 7-MG produce such a wide spectrum of effects because they interact with many different receptors in the brain. Studies have shown that MG and 7-MG interact with alpha-2 adrenergic receptors (adrenaline), D2 dopamine

² Pronounced "Mitra-Guy-Neen."

10

13 14

16

17

15

18

19

20

21

22 23

24

25

26 27 28 receptors, and the serotonin receptors 5-HT2A and 5-HT2C, all of which contribute to the drug's mood-lifting and stimulant-like effects.

- 21. Most crucially, MG and 7-MG also interact with the mu-opioid receptor.
- The mu-opioid receptor is known as "the gateway to addiction" because 22. it is the receptor which all opiates/opioids interact with to produce the classic opiate high: euphoric, sedating, and analgesic. This means that MG and 7-MG interact with the primary receptor that heroin and oxycodone interact with.
- There are other opioid receptors, but the mu-opioid receptor produces the most "hedonic" or habit-forming effects such as euphoria and analgesia.
- Mitragynine and 7-hydroxymitragynine were found to be more potent to 24. the mu-opioid receptor than morphine via oral administration, according to one 2004 study, though the actual effect of kratom is dose-dependent, as discussed above.
- Kratom is therefore considered by health professionals to be similar to 25. an "opioid" and a "quasi-opiate."
- The notion that kratom is substantially similar to an opioid, and a quasi-26. opiate, is reaffirmed by a few facts. First, kratom's effects are very similar to those of other opioids. Second, when administered, kratom alleviates opioid withdrawal symptoms. Third, repeated use of kratom in itself results in opioid withdrawal symptoms.
- All substances which act on the opioid receptors carry a very high risk 27. of addiction, and kratom is no exception.
- 28. Addiction occurs when an opioid is ingested on a regular basis. Over time, the user develops a tolerance to the drug, requiring increased dosages to get the same effects as a lower dose used to have. As the dosages go up, the body becomes dependent on some amount of the drug to feel normal. When the drug is suddenly taken away, the user feels much worse than before they started taking the drug: this is what is known as withdrawal.

- 29. Opioids are addictive not just because of the pleasurable effects that they produce, but because sudden cessation of opioid use causes severe withdrawal symptoms which users feel compelled to avoid by taking more of the drug. The tragedy of addiction is that users want to stop, but they cannot.
- 30. The symptoms of kratom withdrawal are very similar to those of traditional opiate withdrawal. Such symptoms include: irritability, anxiety, difficulty concentrating, depression, sleep disturbance including restless legs, tearing up, runny nose, muscle and bone pain, muscle spasms, diarrhea, decreased appetite, chills, inability to control temperature, and extreme dysphoria and malaise.
- 31. Users typically start substances like kratom because of how good it makes them feel, but, once addicted, they use them to avoid the pain of withdrawal. It no longer is about getting high, but about not feeling "sick."
- 32. With kratom in particular, users note that the addiction sneaks up on them, and that it feels as though, over time, the color has been sapped from their lives. Long term users of kratom have reported experiencing depression, anxiety, anhedonia, and reduced sex drive.

Kratom Use and Addiction in the United States

- 33. Kratom use in the United States has exploded in popularity over the past decade. As of 2021, the American Kratom Association estimates that kratom is a \$1.3 billion a year industry, with 11 million to 15 million annual users in the United States.
- 34. Other studies have found that about 1 million people use kratom in the United States every month. Two-thirds of those users use kratom daily.
- 35. Kratom's popularity can be attributed to a number of factors: first, it is often marketed as a safe substitute for painkillers and appeals to those who falsely equate "natural" with "safe;" second, it has received attention from the media as a "nootropic" or "smart" drug because it is stimulating at low doses; third, its popularity has grown simply because it is so widely available, it produces a

pleasurable high, and it is unregulated; and finally, users are unaware that it is similar to an opioid with opioid addiction potential.

- 36. On the whole, however, kratom is a relatively unknown drug to the average consumer. Most people in the United States have never heard of it.
- 37. The advertisements and commentary about kratom say that it is like a substitute for coffee, a pain reliever, a treatment for opioid withdrawal, an antidepressant, an anti-anxiety supplement, and that it improves focus and gives users a boost of energy to get through the day. These advertisements universally espouse the purported benefits that kratom use can provide, without disclosing that the drug is similar to an opioid with the addictive potential of one.
- 38. What's more, because kratom does not produce a debilitating "high" like cocaine or heroin, it is very easy for users to take the drug every day without feeling as though they are developing a drug addiction or harming themselves. This makes kratom a particularly insidious drug because addiction can sneak up on unsuspecting users and can hold them in its grip despite their best efforts to stop using. The advertisements and word-of-mouth disclosures do not make this clear to consumers.
- 39. Because the manufacturers and advertisers do not disclose the addictive potential of this drug, many users have found themselves blindsided when they wake up one morning in the throes of withdrawal after having stopped using what they thought was an innocuous supplement. They then discover just how painfully dependent they have become on kratom. Because kratom is relatively unknown in the United States, many did not know where to turn for resources and aid. Some users come together on the Internet to share their experiences and support each other as they attempt to get off the drug. There are even well-populated and very active Internet forums serving as support groups for those struggling with and recovering from kratom addiction.

40. The reports from users who have fallen into addiction, or succeeded in escaping the drug's grasp, are heart-wrenching. Consistent amongst these reports is the initial shock that users felt when they realized they had become unwittingly addicted, and just how difficult it was for them to stop. Below are just a few accounts from the "Quitting Kratom" forum on www.reddit.com, which has 33,700 members as of January 2023:

About 8 months ago, one user wrote: "I've been on a 50gpd [grams per day] habit for about 4 years. Like most people here, I was in denial that the Kratom was causing my multitude of issues. How could it be the Kratom when everyone keeps telling me how great it is? I made myself believe that I had underlying issues that the Kratom was helping. Spoiler: It wasn't. I slowly became a shell of the person I used to be. TRUE clinical depression symptoms with zero joy in my life. I started browsing this subreddit and reading everyone's stories and I related to every single one. Everyone had the same exact experience I had and at that moment I knew it was the Kratom causing my depression." (emphasis added).

About 2 years ago, another user wrote: "I saw 'A Leaf of Faith' and got the impression that kratom was a generally friendly substance to use freely, never knowing how addictive it was, how much it was further numbing me beyond how alcohol already was, how it was slowly wiping out my sex drive, and likely contributing to my perpetual brain fog. ... My second attempt [at quitting] was maybe another 7 or 8 months later. Kratom was making me pretty miserable. I was reading posts in this subreddit and I was finally aware of how addicted I was; feeling crappy, sluggish, and sorta spacey pretty much all the time."

About 2 years ago, another user wrote: "What a difficult journey it has been. I was a ~75 GPD [grams per day] user. Quitting kratom was one of the hardest things I've had to do in my life. I learned the hard way that kratom causes withdrawals on a work trip 3 years ago. I should have stopped then and there but I gave in because the RLS was so bad. ... Kratom withdrawal is seriously no joke so don't think you're the only one struggling so much. I'm only a week free but after this experience I know for sure that I will never go back. Good luck everyone!" (emphasis added).

About 2 years ago, another user wrote a post titled *Kratom Is An Addictive Drug*. It said, in part: "It's been 23 hours since my last dose. I just wanted to give my story hoping that it would help others see that they've been lied to, deceived and manipulated into thinking this plant is 'harmless and safe'. As a matter of fact, reading the horror stories on this subreddit was the first step in my recovery... I started taking it almost 3 years ago after hearing about it on...

well, Reddit. They touted it is a miracle plant that had all the benefits of an opioid with none of the side effects." (emphasis added).

About 10 months ago, another user wrote: "I think the perfect word to describe Kratom addiction is 'insidious'. Here is the definition – 'proceeding in a gradual, subtle way, but with harmful effects.' I think this is why it takes so long to realize what is going on. There was never a rock bottom moment for me like there would be for other more conventional abused drugs. No overdose, no bad behavior, no abusiveness to my family, no DWI, etc.. - It was just a lazy, slow descent into nothingness. I was living in a groundhogs day type of existence. Wake up, go to work, leave work, buy an extract shot or 2, have dinner, drink my shot, mindlessly look at my phone and/or watch TV. Wake up and do it all over again." (emphasis in original).

About 3 months ago, another user wrote: "I started using k[ratom] when I had knee surgery Dec 2019 so 3 years. I didn't want to use pain killers because I got sober from alcohol 3/6/2018 and i felt the pain killers were going to make me relapse. I didn't know I would end up in a worst place as I am now." (emphasis added).

About 2 years ago, another user wrote: "Was in bed all day yesterday fighting withdrawals. I used to even be an athlete - strong lean and fit, until I got on [kratom] shots and extracts. Didn't even get high any more - just wanted to not feel bad."

About 4 years ago, another user wrote: "I researched kratom before using it and almost every site promoted that its harmless with healthy benefits, and that its withdrawals are like coffee for 3 days max. Information wasn't clear that kratom could become a negative addiction that takes months to recover" ... "I took something I thought was helping me for 1.5-2 years, not even knowing the downsides be that information was so misleading. It fucked up my digestion, energy, mood, brain fog, anxiety, etc. Fuck kratom, and fuck those who peddle it as a harmless cure-all."

About 1 month ago, another user wrote: "For any newcomers: this stuff is absolutely no joke. It's not harmless and the wd [withdrawal] is *definitely* **not** like caffeine. I've cold turkey'd caffeine before and I had a slight headache for a couple hours. I definitely have never woken up in a pool of my own sweat from not having my caffeine. ... This stuff is a drug. A serious drug. And it's super freakin addictive. Extracts, powder, or in my case, capsules...it doesn't matter. Yes some forms are more addictive than others but the WD is hellacious no matter how you're taking it." (emphasis original).

About 1 month ago, another user wrote: "This stuff is a drug, and dangerous! <u>I</u> started taking it because of all the good things I heard and read about it. I've never been addicted to or dependent on anything before, but this stuff has totally taken control of my life." (emphasis added).

Less than a month ago, another user wrote: "I finally realized a few weeks ago how much of a negative impact kratom was having on my life. I noticed myself planning my whole day around my doses and making sure when I left the house I'd bring an extra dose with me in a shaker bottle. It was heavily affecting my mood overall, but especially in public settings. I did not want to leave my house most days even if I did dose."

- 41. This Internet forum is filled with accounts just like these. The stories are consistent well-meaning people who were looking to feel better, in mind body and spirit, by taking an "herbal supplement," only to end up with an opioid-like addiction.
- 42. What is particularly insidious about kratom is that, at the early stages, many users are unaware of its negative side effects and its addictive potential, so when they begin to experience the malaise of addiction they do not attribute it to the kratom. Rather, they take more of the substance thinking that it is helping them with their malaise.
- 43. As these accounts make clear, the addictive potential of kratom is a material fact to reasonable consumers which would help inform their purchase and consumption decisions. Defendant's products have no information, whatsoever, that kratom is similar to an opioid, is habit-forming, and that regular use will result in opioid-like dependency, with withdrawal symptoms similar to those of traditional opioids.
- 44. Consumers who knew the truth about kratom may not have purchased Defendant's Products or would have paid less than they did for them.

Defendant Knew or Should Have Known it was Selling a Highly Addictive Drug to Unsuspecting Consumers

45. Despite its traditional medical uses, kratom dependence has been known and observed for a long time and is well-documented in Southeast Asia, where the plaint originates and has a longer period of historic use.

- 46. Addiction to kratom among users in Thailand and Malaysia has been documented by scientists and researchers in the United States since at least 1988.
- 47. Upon information and belief, Defendant has interacted with growers and distributors in Southeast Asia who have disclosed the addictive nature of kratom to it.
- 48. Even without such interactions, Defendant has received numerous user reports about the addictive potential of kratom in the United States.
- 49. Defendant therefore knew or should have known that the Products it was selling were highly addictive.
- 50. Despite this knowledge, Defendant has failed to disclose the addictive potential of kratom on its website or on its Products' packaging.
- 51. The furthest that Defendant goes in "disclosing" the addictive nature of kratom is a single sentence buried in the "Learn More" page for its kratom powder product on its website. It states that "scientists are still conducting comprehensive studies to determine whether abusing Kratom causes addiction, death, and withdrawal symptoms." This is deliberately false and misleading. The addictiveness of kratom has been well-documented for decades and is an established fact in medical literature. The pharmacological effects of MG and 7-MG have been thoroughly studied, and it is well-established that MG and 7-MG act on the same mu-opioid receptors in the brain as traditional opioids. Further, there are widespread user reports and case studies of addiction and dependency issues.
- 52. To reiterate, this is not an instance where the science is still up for debate. It has been known for decades in the English-speaking world that kratom is highly addictive and has the potential to cause physical and psychological dependence in regular users. It has been known for over a century in Southeast Asia that kratom is addictive.

- 1
 2
 3

- 53. For example, kratom is the most commonly used drug in Thailand. A 2007 study found that 2.3% of people in Thailand have used kratom. Many of those users have developed a dependence on kratom to avoid withdrawal.
- 54. On information and belief, Defendant imports some of its kratom Products from Thailand.
- 55. Defendant therefore knows or should have known that kratom users can develop an addiction. Yet, Defendant fails to disclose this material fact on its website or its Products' packaging.
- 56. Defendant's Products' packaging, in particular, is woefully sparse. A representative image of Defendant's Products is depicted below:





6

9 10

11 12

14 15

13

16 17

18

19

20 21

22

23

24 25

26 27

- 57. On the back of each Product's packaging is a bog-standard disclaimer stating that the Products are not regulated or evaluated by the FDA.
- 58. There is no warning to consumers that the product interacts with opioid receptors, nor is there any warning that the product is highly addictive and that it should not be taken on a daily basis. To the contrary, the packaging proudly states "All Natural." Further, the company logo includes a pleasant-looking green leaf, and on the back of the packaging there is a banner of a leaf pattern colored with a rainbow. Nothing about this packaging would lead reasonable consumers to believe they were purchasing compounds similar to opioids, that function on the same muopioid receptors in the brain. It looks as innocuous as a vitamin supplement.
- Reasonable consumers looking at the Products' packaging would not presume that kratom is highly addictive.
- 60. Defendant's website is rife with praise for kratom, with no warning that its Products are addictive. For example, upon inspecting the "kratom powder" section of the website, the first sentence they encounter is: "Kratom is not a recent discovery. The truth is it has been around for hundreds of years. This plant-based powder has been growing in popularity recently due to its many benefits and effects."
- A bit further down, Defendant states: "For instance, some loyal Kratom 61. users say they use Kratom to manage and reduce pain. Others say Kratom helps them relax in difficult situations."
- The only warning Defendant gives is its misleading statement that 62. kratom's addictive potential is still being researched.
- The "Kratom Capsules" section of Defendant's website is even more 63. egregious. The first statement Defendant makes is: "Warm greetings to all the Kratom lovers! As we all know, Kratom is a phenomenal herb with some extraordinary benefits to make your daily life more comfortable."

- 64. Further down the page, Defendant states: "When taken in high doses, most Kratom capsules produce effects similar to sedatives or opioids. As a result, some people now use Kratom capsules as an alternative to opioids. Some are even using Kratom capsules to overcome withdrawal symptoms associated with opioid drugs."
- 65. Nowhere does Defendant mention that kratom presents the same addiction problems that former opioid users and other consumers would want to avoid. Those seeking help as they come off opioids may be drawn in by Defendant's statements about kratom without knowing that they risk trading one addiction for another.
- 66. Defendant tries to bolster its credibility by making the half-true claim that "[a] 2021 review by the World Health Organization's expert committee on drug dependence found insufficient evidence of severe effects that can make them add Kratom to the list of internationally controlled substances." However, what Defendant fails to mention is that the same report also states: "in humans, opioid-like withdrawal symptoms have been reported following cessation of kratom use," though "the withdrawal syndrome appears to be less severe than withdrawal from morphine."
- 67. While kratom withdrawal may be "less severe" than morphine withdrawal, that is hardly a seal of approval morphine withdrawal is one of the most unpleasant experiences that one can endure in modern life. And kratom withdrawal, while perhaps "less severe" than morphine withdrawal, is still an "opioid-like withdrawal" (according to the World Health Organization), with the same physical and mental symptoms. And kratom is unquestionably addictive and habit-forming.
- 68. The risk of "opioid-like withdrawal symptoms" is a material fact to reasonable consumers.

8

9 10

11 12

13 14

16

15

17 18

19

20 21

22 23

24

25

26

27

28

- 69. As a kratom product manufacturer and distributor, Defendant occupied a position of superior knowledge to the average reasonable consumer, who likely knows next to nothing about kratom.
- 70. Defendant, through its misleading advertising and its failure to disclose kratom's addictive properties on its Products' labels, relied upon the average consumer's incomplete knowledge of kratom to sell its Products and get users addicted to kratom.
- Defendant fails to disclose kratom's addictive potential because Defendant knows that it is a material fact to reasonable consumers which would influence their purchasing and consumption decisions, likely to Defendant's detriment.
- 72. By any metric, Defendant's conduct is immoral, unethical, and contrary to California public policy.
- The United States is going through an opiate crisis that is shaking the 73. foundations of our society. Amid this crisis, Defendant is creating more addicts for no reason other than to line its pockets, without adequate disclosures of its products' risks and through the use of false and misleading packaging. That cannot – and should not – be allowed, at least when their conduct entails breaches of warranty and violation of state consumer protection statutes (as it does here).

Plaintiffs' Experiences

Plaintiff C.B. first heard about kratom through a friend who did not 74. mention the risks of dependency or addiction. As such, C.B. did not know that kratom was addictive and had no reason to know. He began purchasing Krave branded kratom capsules in 2018. When C.B. made his first purchase, he reviewed the Krave packaging and labels, but there were no disclosures on the bottle that would have corrected his misimpression. Because there were no disclosures, C.B. thought that Krave kratom could be consumed every day without the risk of physical dependence. C.B. soon discovered that Krave kratom was, in fact, addictive, and

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

found himself requiring larger and larger doses to stave off withdrawal. For four years, C.B. took 20-25 grams of Krave Botanicals kratom capsules every day. When C.B. attempted to cease using kratom he was wracked by intense physical and psychological withdrawal symptoms that were substantially similar to traditional opiates. C.B. realized he was addicted to kratom in late 2020 and felt that he was being held captive by the specter of withdrawal. Though C.B. wanted to stop, he could not. At its worst, C.B.'s addiction to Krave kratom was costing him thousands of dollars a month. C.B. was eventually able to kick his addiction to Krave kratom, but not without going through intense physical and psychological withdrawals. Had C.B. known that kratom was so addictive, and that cessation would be so difficult, he would never have purchased Defendant's Products. C.B. made his purchases in and around San Marcos, California.

75. Plaintiff R.V.H. first heard about kratom while listening to the Joe Rogan Experience podcast. The speakers on the show espoused the benefits of the drug without talking about its addictiveness or the terrible withdrawal symptoms. As such, R.V.H. did not know that kratom was addictive and had no reason to know. He began purchasing Krave branded kratom capsules in 2018. When R.V.H. made his first purchase, he reviewed the Krave packaging and labels, but there were no disclosures on the bottle that would have corrected his misimpression. Because there were no disclosures, R.V.H. thought that Krave kratom could be consumed every day without the risk of physical dependence. R.V.H.'s body eventually discovered that Krave kratom was, in fact, addictive, and he found himself requiring larger and larger doses to stave off withdrawal. For four years, R.V.H. took over 50 grams of Krave Botanicals kratom capsules every day. When R.V.H. attempted to cease using kratom he was wracked by intense physical and psychological withdrawal symptoms that were substantially similar to traditional opiates. At its worst, R.V.H.'s addiction to Krave kratom was costing him thousands of dollars a month. He would cash his check at the 8th Street Smoke Shop in Yuma, Arizona, and spend it immediately on

more of the drug. R.V.H. realized he was addicted to kratom in June 2020 and felt that he was being held captive by kratom. Though R.V.H. wanted to stop, he could not. R.V.H. was eventually able to kick his addiction to Krave kratom, but not without going through intense physical and psychological withdrawals and undergoing treatment at a suboxone clinic. Had R.V.H. known that kratom was so addictive, and that cessation would be so difficult, he would never have purchased Defendant's Product. R.V.H. made his purchases in and around Yuma, Arizona. **CLASS ALLEGATIONS**

76. *Class Definitions*. Plaintiffs bring this action pursuant to Code of Civil Procedure § 382 and Civil Code § 1781 on behalf of classes of similarly situated individuals, defined as follows:

All persons nationwide who, within the applicable statute of limitations period, up to and including the date of final judgement in this action, purchased Krave Botanicals kratom products (the "Class")

All Class members in California who, within the applicable statute of limitations period, up to and including the date of final judgment in this action, purchased Krave Botanicals kratom products (the "California Class").

All Class members in Arizona who, within the applicable statute of limitations period, up to and including the date of final judgment in this action, purchased Krave Botanicals kratom products (the "Arizona Class").

- 77. Specifically excluded from the Class are Defendant and any entities in which Defendant have a controlling interest, Defendant's agents and employees, the judge to whom this action is assigned, members of the judge's staff, and the judge's immediate family.
- 78. Plaintiffs reserve the right to amend the definitions of the Classes if discovery or further investigation reveals that the Class should be expanded or otherwise modified.
- 79. *Numerosity*. Members of the Class are so numerous that their individual joinder herein is impracticable. On information and belief, the Class comprises at least thousands of consumers throughout California and the United

States. The precise number of Class members and their identities are unknown to Plaintiffs at this time but may be determined through discovery. Class members may be notified of the pendency of this action by mail and/or publication through the distribution records of Defendant.

- 80. *Commonality and Predominance*. Common questions of law and fact exist as to all Class members and predominate over questions affecting only individual Class members. Common legal and factual questions include, but are not limited to:
 - a. whether the labels on Defendant's Products have the capacity to mislead reasonable consumers;
 - b. whether Defendant knew that kratom is a highly addictive substance;
 - c. whether Defendant's conduct alleged herein violated California's False Advertising Law ("FAL"), Cal. Bus. & Prof. Code §§ 17500, et seq., California's Consumers Legal Remedies Act ("CLRA"), Cal. Civ. Code §§ 1750, et seq., and/or California's Unfair Competition Law ("UCL"), Cal. Bus. & Prof. Code §§ 17200, et seq.;
 - d. whether Defendant's conduct alleged herein constitutes unjust enrichment;
 - e. whether Defendant's conduct constitutes negligent omission;
 - f. whether Plaintiffs and the Class are entitled to damages and/or restitution;
 - g. whether Plaintiffs and the Class are entitled to attorneys' fees and costs under California Code of Civil Procedure § 1021.5.
- 81. *Typicality*. The claims of Plaintiffs are typical of the claims of the Class in that Plaintiffs and the Class sustained damages as a result of Defendant's uniform wrongful conduct, based upon Defendant's failure to inform Plaintiffs and all others similarly situated that its Products are highly addictive and akin to opioids.

- 82. *Adequacy*. Plaintiffs will fairly and adequately protect Class members' interests. Plaintiffs have no interests antagonistic to Class members' interests, and Plaintiffs have retained counsel that have considerable experience and success in prosecuting complex class-actions and consumer-protection cases.
- 83. *Superiority*. A class action is superior to all other available methods for the fair and efficient adjudication of this controversy for, *inter alia*, the following reasons: prosecutions of individual actions are economically impractical for members of the Class; the Class is readily definable; prosecution as a class action avoids repetitious litigation and duplicative litigation costs, conserves judicial resources, and ensures uniformity of decisions; and prosecution as a class action permits claims to be handled in an orderly and expeditious manner.
- 84. Defendant has acted or failed to act on grounds generally applicable to the Class, thereby making appropriate final injunctive relief with respect to the Class as a whole.
- 85. Without a class action, Defendant will continue a course of action that will result in further damages to Plaintiffs and members of the Class and will likely retain the benefits of its wrongdoing.
- 86. Based on the foregoing allegations, Plaintiffs' claims for relief include those set forth below.

FIRST COUNT

Violations of California's Unfair Competition Law ("UCL"), Cal. Bus. & Prof. Code §§ 17200, et seq.

- 87. Plaintiff C.B. re-alleges and incorporates by reference every allegation set forth in the preceding paragraphs as though alleged in this Count.
- 88. Plaintiff C.B. brings this claim individually and on behalf of the members of the proposed California Class against Defendant.
- 89. The UCL prohibits unfair competition in the form of "any unlawful, unfair, or fraudulent business act or practice and unfair, deceptive, untrue or

- 90. As alleged below, Defendant has committed unlawful, fraudulent, and/or unfair business practices under the UCL by: (a) representing that Defendant's Products have certain characteristics that they do not, in violation of Cal. Civil Code § 1770(a)(5); (b) advertising goods and services with the intent not to sell them as advertised, in violation of Cal. Civil Code § 1770(a)(9); (c) selling addictive substances to unsuspecting consumers and profiting from their addiction; and (d) failing to disclose that its Products pose a serious risk of addiction;
- 91. Defendant's conduct has the capacity to mislead a significant portion of the general consuming public or of targeted consumers, acting reasonably in the circumstances.
- 92. Defendant's conduct has injured Plaintiff C.B. and the California Class he seeks to represent in that he paid money for a product that he would not have purchased or paid more than he would have but for Defendant's failure to disclose the addictive nature of its Products. Such injury is not outweighed by any countervailing benefits to consumers or competition. Indeed, no benefit to consumers or competition results from Defendant's conduct. Since consumers reasonably rely on Defendant's labels, and thus also its omissions, consumers could not have reasonably avoided such injury. *Davis v. Ford Motor Credit Co.*, 179 Cal. App. 4th 581, 597-98 (2009); *see also Drum v. San Fernando Valley Bar Ass'n*, 182 Cal. App. 4th 247, 257 (2010) (outlining the third test based on the definition of "unfair" in Section 5 of the FTC Act).

- 93. Pursuant to California Business and Professional Code § 17203, Plaintiff C.B. and the California Class members seek an order of this Court that includes, but is not limited to, an order requiring Defendant to (a) provide restitution to Plaintiff C.B. and the other California Class members; (b) disgorge all revenues obtained as a result of violations of the UCL; and (c) pay Plaintiff C.B. and the California Class members' attorneys' fees and costs.
- 94. Here, equitable relief is appropriate because Plaintiff C.B. may lack an adequate remedy at law if, for instance, damages resulting from their purchase of the Product is determined to be an amount less than the premium price of the Product. Without compensation for the full premium price of the Product, Plaintiff C.B. would be left without the parity in purchasing power to which they are entitled.
- 95. Injunctive relief is also appropriate, and indeed necessary, to require Defendant to provide full and accurate disclosures regarding the Product so that Plaintiff C.B. and the California Class members can reasonably rely on Defendant's packaging as well as those of Defendant's competitors who may then have an incentive to follow Defendant's deceptive practices, further misleading consumers.
- 96. Restitution and/or injunctive relief may also be more certain, prompt, and efficient than other legal remedies requested herein. The return of the full premium price, and an injunction requiring Defendant to disclose on its Products' packaging that kratom is addictive will ensure that Plaintiff C.B. is in the same place he would have been in had Defendant's wrongful conduct not occurred, *i.e.*, in the position to make an informed decision about the purchase of the Products absent omissions with the full purchase price at their disposal.

SECOND COUNT

Violation of California's Consumers Legal Remedies Act, Cal. Civ. Code §§ 1750, et seq.

97. Plaintiff C.B. realleges and reincorporates by reference all paragraphs alleged above.

- 98. Plaintiff C.B. brings this claim individually and on behalf of the California Class against Defendant.
- 99. Plaintiff C.B. and California Class Members are consumers within the meaning of Cal. Civ. Code § 1761(d).
- 100. Cal. Civ. Code § 1770(a)(5) prohibits "[r]epresenting that goods or services have sponsorship, approval, characteristics, ingredients, uses, benefits, or quantities which they do not have or that a person has a sponsorship, approval, status, affiliation, or connection which she or she does not have."
- 101. Cal. Civ. Code § 1770(a)(7) prohibits "[r]epresenting that goods or services are of a particular standard, quality, or grade, or that goods are of a particular style or model, if they are of another."
- 102. Cal. Civ. Code § 1770(a)(9) prohibits "advertising goods or services with intent not to sell them as advertised."
- 103. Defendant violated Cal. Civ. Code §§ 1770(a)(5), (a)(7), and (a)(9) by intentionally and misleadingly representing that its Products are "all natural" and by failing to disclose that its Products are addictive, a fact which is material to reasonable consumers.
- 104. Defendant's misrepresentations and omissions deceive and have a tendency and ability to deceive the general public.
- 105. Defendant has exclusive or superior knowledge of kratom's addictive nature, which was not known to Plaintiff C.B. or California Class Members.
- 106. Plaintiff C.B. and California Class Members have suffered harm as a result of these violations of the California Consumers Legal Remedies Act, Cal. Civ. Code §§ 1750, *et seq.* ("CLRA") because they have incurred charges and/or paid monies for the Products that they otherwise would not have incurred or paid had they known that kratom is addictive and causes withdrawals. As a result, Plaintiff C.B. and the California Class are entitled to actual damages in an amount to be proven at trial, reasonable attorneys' fees and costs, declaratory relief, and punitive damages.

107. On January 18, 2023, Plaintiff C.B.'s counsel sent Defendant a CLRA notice letter, which complies in all respects with Cal. Civ. Code § 1782(a). The letter was sent via certified mail, return receipt requested, advising Defendant that it was in violation of the CLRA and demanding that it cease and desist from such violations and make full restitution by refunding the monies received therefrom. The letter stated that it was sent on behalf of all other similarly situated purchasers.

THIRD COUNT

Violation of California's False Advertising Law, Cal. Bus. & Prof. Code §§ 17500, et seq.

- 108. Plaintiff C.B. realleges and reincorporates by reference all paragraphs alleged above.
- 109. Plaintiff C.B. brings this claim individually and on behalf of the California Class against Defendant.
- 110. Defendant's acts and practices, as described herein, have deceived and/or are likely to continue to deceive California Class Members and the public. As described above, and throughout this Complaint, Defendant misrepresented that kratom is not addictive. Such representation is not true.
- 111. By its actions, Defendant disseminated uniform advertising regarding its kratom Products to and across California. The advertising was, by its very nature, unfair, deceptive, untrue, and misleading within the meaning of California's False Advertising Law, Cal. Bus. & Prof. Code §§ 17500, et seq. (the "FAL"). Such advertisements were intended to and likely did deceive the consuming public for the reasons detailed herein.
- 112. The above-described false, misleading, and deceptive advertising Defendant disseminated continues to have a likelihood to deceive in that Defendant continues to misrepresent, without qualification, that kratom is not addictive.
- 113. In making and disseminating these statements, Defendant knew, or should have known, its advertisements were untrue and misleading in violation of

6

11

12

10

13 14

15

16 17

18

19

20 21

22

23

24 25

26 27

28

California law. Defendant knows that kratom is addictive yet fails to disclose this fact to consumers.

- 114. Plaintiff C.B. and other California Class Members purchased Krave Kratom based on Defendant's representations and omissions that kratom is not addictive.
- The misrepresentations and non-disclosures by Defendant of the material facts described and detailed herein constitute false and misleading advertising and, therefore, constitutes a violation of the FAL.
- 116. As a result of Defendant's wrongful conduct, Plaintiff C.B. and California Class Members lost money in an amount to be proven at trial. Plaintiff C.B. and California Class Members are therefore entitled to restitution as appropriate for this cause of action.
- 117. Plaintiff C.B. and California Class Members seek all monetary and nonmonetary relief allowed by law, including restitution of all profits stemming from Defendant's unfair, unlawful, and fraudulent business practices; declaratory relief; reasonable attorneys' fees and costs under Cal. Code Civ. Proc. § 1021.5; and other appropriate equitable relief.

FOURTH COUNT Breach of Implied Warranty

- 118. Plaintiffs reallege and reincorporate by reference all paragraphs alleged above.
- 119. Plaintiffs bring this claim individually and on behalf of the nationwide Class, California Class, and Arizona Class against Defendant.
- 120. Defendant, as the designer, manufacturer, marketer, distributor, and/or seller of the Products, impliedly warranted that kratom is not addictive and does not cause opioid-like withdrawal symptoms because it did not provide a of disclosure on the Products' packaging stating otherwise.

- 121. Defendant breached its warranty implied in the contract for the sale of its kratom Products because the Products could not pass without objection in the trade under the contract description: the kratom Products were not adequately contained, packaged, and labeled as per Defendant's contract with Plaintiffs and members of the Class, and the Products do not conform to the implied affirmations of fact made on the marketing and packaging for the Products that the Products are not addictive and do not cause withdrawals. U.C.C. §§ 2-313(2)(a), (e), (f). As a result, Plaintiffs and members of the Classes did not receive the goods as impliedly warranted by Defendant to be merchantable.
- 122. Plaintiffs and members of the Class purchased the Products in reliance upon Defendant's skill and judgment and the implied warranties of fitness for the purpose.
- 123. The kratom Products were defective when they left the exclusive control of Defendant.
- 124. Plaintiffs and members of the Class did not receive the goods as warranted.
- 125. As a direct and proximate cause of Defendant's breach of the implied warranty, Plaintiffs and members of the Class have been injured and harmed because: (a) they would not have purchased Krave Kratom on the same terms if they knew that the Product was addictive and could cause opioid-like withdrawal symptoms; and (b) the Products do not have the characteristics, uses, or benefits as promised by Defendant.
- 126. On January 18, 2023, prior to filing this action, Defendant was served with a pre-suit notice letters on behalf of Plaintiffs that complied in all respects with U.C.C. §§ 2-314 and 2-607. Plaintiffs' counsel sent Defendant a letter advising Defendant that it breached an implied warranty and demanded that Defendant cease and desist from such breaches and make full restitution by refunding the monies received therefrom.

FIFTH COUNT Unjust Enrichment

- 127. Plaintiffs incorporate by reference the foregoing paragraphs of this Complaint as if fully stated herein.
- 128. Plaintiffs bring this claim individually and on behalf of the members of the nationwide Class, California Class, and Arizona Class against Defendant.
- 129. Plaintiffs and the Class members conferred a benefit on Defendant in the form of the gross revenues Defendant derived from the money they paid to Defendant.
- 130. Defendant had an appreciation or knowledge of the benefit conferred on it by Plaintiffs and the Class members.
- 131. Defendant has been unjustly enriched in retaining the revenues derived from Plaintiffs and the Class members' purchases of the Products, which retention of such revenues under these circumstances is unjust and inequitable because Defendant omitted that the Products were addictive and similar to opioids. This caused injuries to Plaintiffs and members of the Classes because they would not have purchased the Products or would have paid less for them if the true facts concerning the Products had been known.
- 132. Defendant accepted and retained the benefit in the amount of the gross revenues it derived from sales of the Products to Plaintiffs and the Class members.
- 133. Defendant has thereby profited by retaining the benefit under circumstances which would make it unjust for Defendant to retain the benefit.
- 134. Plaintiffs and the Class members are, therefore, entitled to restitution in the form of the revenues derived from Defendant's sale of the Products.
- 135. As a direct and proximate result of Defendant's actions, Plaintiffs and the members of the Class have suffered in an amount to be proven at trial.

- 136. Here, equitable relief is appropriate because Plaintiffs may lack an adequate remedy at law if, for instance, damages resulting from their purchase of the Product is determined to be an amount less than the premium price of the Product. Without compensation for the full premium price of the Product, Plaintiffs would be left without the parity in purchasing power to which they are entitled.
- 137. Injunctive relief is also appropriate, and indeed necessary, to require Defendant to provide full and accurate disclosures regarding the Product so that Plaintiffs and Class members can reasonably rely on Defendant's packaging as well as those of Defendant's competitors who may then have an incentive to follow Defendant's deceptive practices, further misleading consumers.
- 138. Restitution may also be more certain, prompt, and efficient than other legal remedies requested herein. The return of the full premium price will ensure that Plaintiffs are in the same place they would have been in had Defendant's wrongful conduct not occurred, i.e., in the position to make an informed decision about the purchase of the Products absent omissions with the full purchase price at their disposal.

SIXTH COUNT Fraud by Omission

- 139. Plaintiffs reallege and reincorporate by reference all paragraphs alleged above.
- 140. Plaintiffs bring this claim individually and on behalf of the nationwide Class, California Class, and Arizona Class against Defendant.
 - 141. Defendant Ashlynn Marketing, Inc., is located in Santee, California.
- 142. Defendant distributed its Products throughout the State of California and the Nation.
- 143. Defendant misrepresented that its kratom Products have attributes or qualities that they do not have by failing to disclose that kratom is addictive and can cause opioid-like withdrawal.

- 144. Defendant knows that kratom is addictive because it interacts with kratom vendors and has been made aware of user reports.
- 145. Defendant knows that knowledge of kratom's addictive nature is a material fact that would influence the purchasing decision of reasonable consumers.
- 146. The average reasonable consumer in the kratom purchasing context does not know that kratom is addictive and cannot reasonably access that information.
- 147. Defendant therefore had a duty to Plaintiffs and the Class members to disclose that kratom is addictive and can cause withdrawals on the Products' packaging.
- 148. Consumers reasonably and justifiably relied on Defendant's omission because it is reasonable to assume that a product which is addictive like an opioid would bear a warning.
- 149. As a result of Defendant's omission, Plaintiffs and the Class members paid for kratom Products they may not have purchased, or paid more for those Products than they would have had they known the truth about kratom.

SEVENTH COUNT Negligent Misrepresentation

- 150. Plaintiffs reallege and reincorporate by reference all paragraphs alleged above.
- 151. Plaintiffs bring this claim individually and on behalf of the nationwide Class, California Class, and Arizona Class against Defendant.
- 152. Defendant Ashlynn Marketing, Inc. is headquartered in Santee, California.
 - 153. Defendant distributed its Products throughout the state of California.
- 154. Defendant misrepresented that its kratom Products have attributes or qualities that they do not have by failing to disclose that kratom is addictive and can cause opioid-like withdrawal.

- 155. Defendant knew or should have known that kratom is addictive because it interacts with kratom vendors and has been made aware of user reports and scientific studies.
- 156. Defendant knew or should have known that knowledge of kratom's addictive nature is a material fact that would influence the purchasing decision of reasonable consumers.
- 157. The average reasonable consumer in the kratom purchasing context does not know that kratom is addictive and cannot reasonably access that information.
- 158. Defendant therefore had a duty to Plaintiffs and the Class members to disclose that kratom is addictive and can cause withdrawals on the Products' packaging.
- 159. Consumers reasonably and justifiably relied on Defendant's omission because it is reasonable to assume that a product which is addictive like an opioid would bear some kind of a warning.
- 160. As a result of Defendant's omission, Plaintiffs and the Class members paid for kratom Products they may not have purchased or paid more for those Products than they would have had they known the truth about kratom.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs C.B. and R.V.H., individually and on behalf of all others similarly situated, seek judgment against Defendant, as follows:

- a. For an order certifying the Class and naming Plaintiffs as the representatives of the Class, naming Plaintiff C.B. as representative of the California Class, Plaintiff R.V.H. as representative of the Arizona Class, and naming Plaintiffs' attorneys as Class Counsel to represent the Class, California Class, and Arizona Class;
- b. For an order declaring Defendant's conduct violates the statutes referenced herein;

1 2	c.	For an order find asserted herein;	ding in favor of Plaintiffs and the Class on all counts
3	d.	For actual, compensatory, statutory, and/or punitive damages in amounts to be determined by the Court and/or jury;	
4	e.	For prejudgment interest on all amounts awarded;	
5 6	f.	For an order of restitution and all other forms of equitable monetary relief;	
7	g.	For injunctive relief as pleaded or as the Court may deem proper; and	
8	h.	For an order awarding Plaintiffs and the Class their reasonable attorneys' fees, expenses, and costs of suit.	
9	JURY TRIAL DEMANDED		
10	Plaintiffs demand a trial by jury on all claims so triable.		
11			
12	Dated: An	ril 13 2023	Respectfully submitted,
13			
14			BURSOR & FISHER, P.A.
15			By:/s/Neal J. Deckant
16			Neal J. Deckant
17			Neal J. Deckant (State Bar No. 322946)
18			Luke Sironski-White (State Bar No. 348441) 1990 North California Blvd., Suite 940
19			Walnut Creek, CA 94596
20			Telephone: (925) 300-4455
21			Facsimile: (925) 407-2700 E-mail: ndeckant@bursor.com
22			lsironski@bursor.com
23			Attorneys for Plaintiffs
24			
25			
26			
27			
28			

CLRA Venue Declaration Pursuant to California Civil Code Section 1780(d)

- I, Neal J. Deckant, declare as follows:
- 1. I am counsel for Plaintiffs, and I am a partner at Bursor & Fisher, P.A. I make this declaration to the best of my knowledge, information, and belief of the facts stated herein.
- 2. The complaint filed in this action is filed in the proper place for trial because many of the acts and transactions giving rise to this action occurred in this District, and because Plaintiff C.B. resides in this District.
- 3. Plaintiff C.B. alleges that he is a citizen of California and resident of Encinitas, California.
- 4. Defendant Ashlynn Marketing Group is a California corporation with its principal place of business in Santee, California.

I declare under penalty of perjury under the laws of the United States and the State of California that the foregoing is true and correct, executed on April 13, 2023 at Walnut Creek, California.

/s/ Neal J. Deckant
Neal J. Deckant

ClassAction.org

This complaint is part of ClassAction.org's searchable class action lawsuit database and can be found in this post: <u>Krave Botanicals Misled Consumers About Highly Addictive Kratom Products</u>, <u>Class Action Claims</u>